Companies Prime Medicine, Inc.
Prime Medicine (PRME): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Prime Medicine, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $4,623,802FY2024
- $3,894,187FY2025
CEO total pay was $3,894,187 in fiscal 2025, down from $4,623,802 in fiscal 2024.
FY2025: salary $606,212 · bonus $0 · stock awards $0 · option awards $2,828,798
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Allan Reine | $606,212 | $0 | $0 | $2,828,798 | $402,000 | $0 | $57,177 | $3,894,187 |
| Chief Executive Officer | ||||||||
| Keith Gottesdiener | 259,568 | 0 | 0 | 1,185,802 | 0 | 0 | 762,400 | 2,207,770 |
| Former Chief Executive Officer | ||||||||
| Ann Lee | 505,375 | 0 | 0 | 790,075 | 243,960 | 0 | 10,706 | 1,550,116 |
| Chief Technical Officer | ||||||||
| Jeremy Duffield | 268,271 | 0 | 0 | 668,600 | 0 | 0 | 380,926 | 1,317,797 |
| Former Chief Scientific Officer | ||||||||
| Jeremy FRCP | 268,271 | 0 | 0 | 668,600 | 0 | 0 | 380,926 | 1,317,797 |
| Former Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Allan Reine | $3,894,187 | $4,623,802 | — | ↓ −729,615 |
| Keith Gottesdiener | 2,207,770 | 2,245,617 | 5,403,071 | ↓ −37,847 |
| Ann Lee | 1,550,116 | — | 2,264,362 | — |
| Jeremy Duffield | 1,317,797 | — | — | — |
| Jeremy FRCP | 1,317,797 | 1,877,577 | 2,260,230 | ↓ −559,780 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, motivate and retain key employees who best represent our values and can make significant contributions towards achieving our purpose of delivering a new class of differentiated one-time curative genetic therapies. The program reflects a pay-for-performance philosophy that supports our business strategy by incentivizing executives based on the achievement of key strategic and business goals, while aligning their interests with those of our stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ann Lee | OPTION | 2025-08-01 | — | — | 180,995 | — | $197,786 |
| Ann Lee | OPTION | 2025-08-01 | — | — | 180,995 | — | 120,691 |
| Ann Lee | OPTION | 2025-02-27 | — | — | 275,000 | — | 471,598 |
| Jeremy FRCP | OPTION | 2025-02-27 | — | — | 275,000 | — | 471,598 |
| Jeremy Duffield | OPTION | 2025-02-27 | — | — | — | — | 471,598 |
| Keith Gottesdiener | OPTION | 2025-02-28 | — | — | 500,000 | — | 892,200 |
| David Schenkein, M.D | OPTION | 2025-02-27 | — | — | 275,000 | — | 471,598 |
| David Schenkein, M.D | OPTION | 2025-05-19 | — | — | 2,000,000 | — | 1,911,400 |
| David Schenkein, M.D | OPTION | 2025-08-01 | — | — | 850,000 | — | 445,801 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ann Lee | $0 | $0 | $790,075 | 0.0% |
| Jeremy FRCP | 0 | 0 | 471,598 | 0.0% |
| Jeremy Duffield | 0 | 0 | 471,598 | 0.0% |
| Keith Gottesdiener | 0 | 0 | 892,200 | 0.0% |
| David Schenkein, M.D | 0 | 0 | 2,828,799 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Keith Gottesdiener | Option | 54,167 | 8.32 | — |
| Ann Lee | Option | 56,561 | 4.04 | — |
| Jeremy Duffield | Option | 56,561 | 12.3 | — |
| Ann Lee | Option | 98,039 | 4.04 | — |
| Jeremy Duffield | Option | 98,039 | 8.49 | — |
| Keith Gottesdiener | Option | 155,544 | 12.3 | — |
| Allan Reine | Option | 217,709 | 2.42 | — |
| Ann Lee | Option | 217,709 | 2.42 | — |
| Jeremy Duffield | Option | 217,709 | 2.42 | — |
| Allan Reine | Option | 312,500 | 4.04 | — |
| Keith Gottesdiener | Option | 395,834 | 2.52 | — |
| Allan Reine | Option | 2,000,000 | 1.34 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jeffrey D. MarrazzoNot independent · Board Chair | $45,000 | — | $1,199,949 | — | $95,161 | $1,340,110 |
| Michael KellyIndependent · Audit Committee (Chair) | 65,000 | — | 162,079 | — | 0 | 227,079 |
| Kaye FosterIndependent · Compensation Committee (Chair) | 60,000 | — | 162,359 | — | 0 | 222,359 |
| Wendy Chung, M.D., Ph.DIndependent · Audit Committee · Nominating and Corporate Governance Committee | 60,000 | 0 | 162,079 | 0 | 0 | 222,079 |
| David Schenkein, M.DIndependent · Compensation Committee | 62,500 | — | 133,924 | — | 0 | 196,424 |
| Thomas Cahill, M.D., Ph.DIndependent · Audit Committee · Nominating and Corporate Governance Committee | 60,000 | 0 | 133,924 | 0 | 0 | 193,924 |
| Robert NelsenIndependent · Compensation Committee | 52,500 | — | 133,924 | — | 0 | 186,424 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $405,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $95,161 |
| Total cost of the board | $500,161 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Prime Medicine as a peer
Companies that benchmark against PRME
7 companies name PRME as a compensation peer
The list of companies that name PRME as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Prime Medicine, Inc. | 2025 | Allan Reine | $606,212 | $0 | $2,828,798 | $402,000 | $3,894,187 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-08-01 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-08-01 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Kelly | Director | 2026-06-05 | A | 75,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Nelsen | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Marrazzo | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Cahill | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Wendy Chung | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David P. Schenkein | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kaye I. Foster-Cheek | Director | 2026-06-05 | A | 75,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (34 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Allan Reine. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · page 23. As printed: 3,894,187. View filing ↗
- Section 01, Keith Gottesdiener. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 2,207,770. View filing ↗
- Section 01, Ann Lee. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 1,550,116. View filing ↗
- Section 01, Jeremy Duffield. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 1,317,797. View filing ↗
- Section 01, Jeremy FRCP. DEF 14A, filed 2026-04-23. Section “Executive Compensation”. As printed: 1,317,797. View filing ↗
- Section 03, Ann Lee OPTION. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ann Lee OPTION. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Ann Lee OPTION. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeremy FRCP OPTION. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeremy Duffield OPTION. DEF 14A, filed 2026-04-23. Section “M.D.” · grants of plan-based awards table. View filing ↗
- Section 03, Keith Gottesdiener OPTION. DEF 14A, filed 2026-04-23. Section “M.D.” · grants of plan-based awards table. View filing ↗
- Section 03, David Schenkein, M.D OPTION. DEF 14A, filed 2026-04-23. Section “M.D.” · grants of plan-based awards table. View filing ↗
- Section 03, David Schenkein, M.D OPTION. DEF 14A, filed 2026-04-23. Section “M.D.” · grants of plan-based awards table. View filing ↗
- Section 03, David Schenkein, M.D OPTION. DEF 14A, filed 2026-04-23. Section “M.D.” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-03. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Jeffrey D. Marrazzo. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 1,340,110. View filing ↗
- Section 08, Michael Kelly. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 227,079. View filing ↗
- Section 08, Kaye Foster. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 222,359. View filing ↗
- Section 08, Wendy Chung, M.D., Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 222,079. View filing ↗
- Section 08, David Schenkein, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 196,424. View filing ↗
- Section 08, Thomas Cahill, M.D., Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 193,924. View filing ↗
- Section 08, Robert Nelsen. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 186,424. View filing ↗
- Section 02, Michael Kelly 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Nelsen 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey D. Marrazzo 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Cahill 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wendy Chung 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David P. Schenkein 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kaye I. Foster-Cheek 2026-06-05. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-08-05. Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 71,563,193). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 405,000 + equity 0 + all other 95,161 = 500,161, summed across the director compensation table rows.
- Prime Medicine, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. View filing ↗